Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by RTOon May 01, 2014 9:29pm

147 Views

Post# 22515602

RE:RE:RE:RE:Warrants In The Money??

Melone, actually there is a 3 fold 'difference' on the warrant value. The proposed term warrants (.50us) are worth 3 times MORE on my spreadsheet. This share price volatility of late is having a very positive impact on the "volatility variance' percentage. Imo, the warrants should catch up once the big boys rap their heads around the complicated terms. This is why I worked this out months ago. Good luck!

Bullboard Posts

How one company is disrupting PoC testing